Loading...
Asthma patients who use over-the-counter epinephrine inhalers (marketed as Primatene Mist) will need to switch to a different treatment by the end of the year, the FDA reminded clinicians and patients on Thursday.
Epinephrine inhalers use chlorofluorocarbons to propel the medication into the lungs. They are being phased out in order to comply with an international agreement that bans CFCs because they deplete the ozone layer.
None of the replacement treatment options are over-the-counter, so patients will need to obtain a prescription for their new medication. The prescription medications are more expensive than the epinephrine inhalers.
Comment
LINK(S):
FDA news release (Free)
FDA Q & A about epinephrine inhalers (Free)
Previous Physician's First Watch coverage of transition to CFC-free inhalers (Free)